Supernus Pharmaceuticals - 14 Year Stock Price History | SUPN
Historical daily share price chart and data for Supernus Pharmaceuticals since 2012 adjusted for splits and dividends. The latest closing stock price for Supernus Pharmaceuticals as of September 17, 2026 is 42.92.
- The all-time high Supernus Pharmaceuticals stock closing price was 59.85 on June 29, 2018.
- The Supernus Pharmaceuticals 52-week high stock price is 59.68, which is 39% above the current share price.
- The Supernus Pharmaceuticals 52-week low stock price is 40.51, which is 5.6% below the current share price.
- The average Supernus Pharmaceuticals stock price for the last 52 weeks is 48.41.
| Supernus Pharmaceuticals Historical Annual Stock Price Data | ||||||
|---|---|---|---|---|---|---|
| Year | Average Stock Price | Year Open | Year High | Year Low | Year Close | Annual % Change |
| 2026 | 48.3825 | 49.4700 | 56.3200 | 41.2800 | 42.9200 | -13.64% |
| 2025 | 39.2089 | 36.4300 | 57.0000 | 30.2900 | 49.7000 | 37.44% |
| 2024 | 31.3219 | 27.7300 | 37.8300 | 25.7700 | 36.1600 | 24.95% |
| 2023 | 32.5666 | 37.4700 | 42.0300 | 22.7200 | 28.9400 | -18.87% |
| 2022 | 31.6678 | 30.0800 | 37.8800 | 25.3300 | 35.6700 | 22.33% |
| 2021 | 28.9560 | 25.1400 | 34.2200 | 23.5400 | 29.1600 | 15.90% |
| 2020 | 21.8370 | 23.7100 | 25.8100 | 14.4500 | 25.1600 | 6.07% |
| 2019 | 31.2652 | 32.7700 | 41.9900 | 19.9300 | 23.7200 | -28.60% |
| 2018 | 46.5386 | 40.4500 | 59.8500 | 30.8400 | 33.2200 | -16.64% |
| 2017 | 36.3333 | 25.9500 | 49.6500 | 23.4500 | 39.8500 | 57.82% |
| 2016 | 18.9972 | 13.1400 | 26.6800 | 10.1300 | 25.2500 | 87.87% |
| 2015 | 14.4964 | 8.2200 | 21.2600 | 8.1800 | 13.4400 | 61.93% |
| 2014 | 8.8842 | 7.6500 | 11.1300 | 7.3200 | 8.3000 | 10.08% |
| 2013 | 6.6794 | 7.2900 | 8.3800 | 4.5100 | 7.5400 | 5.16% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $2.409B | $0.719B |
| Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |